RecruitingNot ApplicableNCT05709210
Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease
Sponsor
Poitiers University Hospital
Enrollment
90 participants
Start Date
Jul 20, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or Alzheimer's disease.
Eligibility
Min Age: 60 Years
Plain Language Summary
Simplified for easier understanding
This study is exploring whether data collected from a person's smartphone — such as how they type, move, and use their device — can be used as an early marker to help diagnose Alzheimer's disease.
**You may be eligible if...**
- You are a patient receiving routine care at a memory clinic
- You have no sensory impairments that would prevent you from using a smartphone normally
**You may NOT be eligible if...**
- Your cognitive test score (MMSE) is below 20, or you cannot complete the test
- You have another type of brain condition (such as Parkinson's disease, Lewy body disease, or ALS)
- You have severe anxiety or depression
- You have a serious illness in its final stages
- You have a brain lesion on MRI that may be causing cognitive problems
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERRecording of smartphone usage data
Recording of smartphone usage data
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05709210
Related Trials
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT0684732135 locations
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
NCT07011745140 locations
Development, Standardisation and Standardisation Project for a New Memory Assessment
NCT065647791 location
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732157 locations
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787288 locations